Midostaurin with standard chemotherapy in FLT3-positive acute myeloid leukaemia
Finnish Medicines Agency, Norwegian Medicines Agency
Record ID 32018001031
English
Authors' objectives:
This is a Rapid Relative Effectiveness Assessment of midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for patients in complete response, followed by midostaurin monotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://eunethta.eu/final-assessment-report-on-midostaurin-rydapt-in-combination-with-standard-daunorubicin-and-cytarabine-induction-and-high-dose-cytarabine-consolidation-chemotherapy/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Protein Kinase Inhibitors
- Staurosporine
- Adult
- Young Adult
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
Copyright:
CC-BY-NC:
You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.